Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 139

1.

Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations.

Rogliani P, Matera MG, Ritondo BL, De Guido I, Puxeddu E, Cazzola M, Calzetta L.

Pulm Pharmacol Ther. 2019 Sep 11:101841. doi: 10.1016/j.pupt.2019.101841. [Epub ahead of print]

PMID:
31520718
2.

A potential role of triple therapy for asthma patients.

Cazzola M, Puxeddu E, Matera MG, Rogliani P.

Expert Rev Respir Med. 2019 Sep 1:1-7. doi: 10.1080/17476348.2019.1657408. [Epub ahead of print]

PMID:
31422716
3.

Evolving Concepts in Chronic Obstructive Pulmonary Disease Blood-Based Biomarkers.

Cazzola M, Puxeddu E, Ora J, Rogliani P.

Mol Diagn Ther. 2019 Jul 18. doi: 10.1007/s40291-019-00413-1. [Epub ahead of print] Review.

PMID:
31363933
4.

CD71-Alveolar Macrophages in IPF: a Look Beyond the Borders of the Disease.

Puxeddu E, Fraboni D, Cillis G, Cavalli F, Buccisano F, Rogliani P.

Am J Respir Crit Care Med. 2019 Jul 26. doi: 10.1164/rccm.201906-1159LE. [Epub ahead of print] No abstract available.

PMID:
31347921
5.

Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy.

Locati LD, Piovesan A, Durante C, Bregni M, Castagna MG, Zovato S, Giusti M, Ibrahim T, Puxeddu E, Fedele G, Pellegriti G, Rinaldi G, Giuffrida D, Verderame F, Bertolini F, Bergamini C, Nervo A, Grani G, Rizzati S, Morelli S, Puliafito I, Elisei R.

Eur J Cancer. 2019 Sep;118:35-40. doi: 10.1016/j.ejca.2019.05.031. Epub 2019 Jul 9.

PMID:
31299580
6.

Methylglyoxal Acts as a Tumor-Promoting Factor in Anaplastic Thyroid Cancer.

Antognelli C, Moretti S, Frosini R, Puxeddu E, Sidoni A, Talesa VN.

Cells. 2019 Jun 6;8(6). pii: E547. doi: 10.3390/cells8060547.

7.

Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine.

Rogliani P, Matera MG, Page C, Puxeddu E, Cazzola M, Calzetta L.

Respir Res. 2019 May 27;20(1):104. doi: 10.1186/s12931-019-1078-y.

8.

Immune Profiling of Thyroid Carcinomas Suggests the Existence of Two Major Phenotypes: An ATC-Like and a PDTC-Like.

Giannini R, Moretti S, Ugolini C, Macerola E, Menicali E, Nucci N, Morelli S, Colella R, Mandarano M, Sidoni A, Panfili M, Basolo F, Puxeddu E.

J Clin Endocrinol Metab. 2019 Aug 1;104(8):3557-3575. doi: 10.1210/jc.2018-01167.

PMID:
30882858
9.

The prognostic role of Gender-Age-Physiology system in idiopathic pulmonary fibrosis patients treated with pirfenidone.

Harari S, Caminati A, Confalonieri M, Poletti V, Vancheri C, Pesci A, Rogliani P, Luppi F, Agostini C, Rottoli P, Sanduzzi Zamparelli A, Sebastiani A, Della Porta R, Salton F, Messore B, Tomassetti S, Rosso R, Biffi A, Puxeddu E, Cerri S, Cinetto F, Refini RM, Bocchino M, Di Michele L, Specchia C, Albera C; ILDINET (Interstitial Lung Diseases Italian Network).

Clin Respir J. 2019 Mar;13(3):166-173. doi: 10.1111/crj.12999.

PMID:
30675755
10.

BRAF V600E Confers Male Sex Disease-Specific Mortality Risk in Patients With Papillary Thyroid Cancer.

Wang F, Zhao S, Shen X, Zhu G, Liu R, Viola D, Elisei R, Puxeddu E, Fugazzola L, Colombo C, Jarzab B, Czarniecka A, Lam AK, Mian C, Vianello F, Yip L, Riesco-Eizaguirre G, Santisteban P, O'Neill CJ, Sywak MS, Clifton-Bligh R, Bendlova B, Sýkorová V, Wang Y, Xing M.

J Clin Oncol. 2018 Sep 20;36(27):2787-2795. doi: 10.1200/JCO.2018.78.5097. Epub 2018 Aug 2.

11.

Bronchoalveolar lavage (BAL) cells in idiopathic pulmonary fibrosis express a complex pro-inflammatory, pro-repair, angiogenic activation pattern, likely associated with macrophage iron accumulation.

Lee J, Arisi I, Puxeddu E, Mramba LK, Amicosante M, Swaisgood CM, Pallante M, Brantly ML, Sköld CM, Saltini C.

PLoS One. 2018 Apr 12;13(4):e0194803. doi: 10.1371/journal.pone.0194803. eCollection 2018. Erratum in: PLoS One. 2018 May 17;13(5):e0197794.

12.

Emerging biological therapies for treating chronic obstructive pulmonary disease: A pairwise and network meta-analysis.

Rogliani P, Matera MG, Puxeddu E, Mantero M, Blasi F, Cazzola M, Calzetta L.

Pulm Pharmacol Ther. 2018 Jun;50:28-37. doi: 10.1016/j.pupt.2018.03.004. Epub 2018 Mar 30.

PMID:
29609004
13.

Anti-hTERT siRNA-Loaded Nanoparticles Block the Growth of Anaplastic Thyroid Cancer Xenograft.

Lombardo GE, Maggisano V, Celano M, Cosco D, Mignogna C, Baldan F, Lepore SM, Allegri L, Moretti S, Durante C, Damante G, Fresta M, Russo D, Bulotta S, Puxeddu E.

Mol Cancer Ther. 2018 Jun;17(6):1187-1195. doi: 10.1158/1535-7163.MCT-17-0559. Epub 2018 Mar 21.

14.

A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD.

Matera MG, Calzetta L, Puxeddu E, Rogliani P, Cazzola M.

Expert Opin Drug Saf. 2018 May;17(5):509-517. doi: 10.1080/14740338.2018.1448786. Epub 2018 Mar 8.

PMID:
29505318
15.

Long glucocorticoid-induced leucine zipper regulates human thyroid cancer cell proliferation.

Ayroldi E, Petrillo MG, Marchetti MC, Cannarile L, Ronchetti S, Ricci E, Cari L, Avenia N, Moretti S, Puxeddu E, Riccardi C.

Cell Death Dis. 2018 Feb 21;9(3):305. doi: 10.1038/s41419-018-0346-y.

16.

Therapeutic use of heparin and derivatives beyond anticoagulation in patients with bronchial asthma or COPD.

Shute JK, Puxeddu E, Calzetta L.

Curr Opin Pharmacol. 2018 Jun;40:39-45. doi: 10.1016/j.coph.2018.01.006. Epub 2018 Feb 20. Review.

PMID:
29455115
17.

Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study.

Rogliani P, Ora J, Puxeddu E, Calzetta L, Cavalli F, Matera MG, Cazzola M.

Pulm Pharmacol Ther. 2018 Apr;49:20-26. doi: 10.1016/j.pupt.2017.12.010. Epub 2017 Dec 30.

PMID:
29294360
18.

Patient Age-Associated Mortality Risk Is Differentiated by BRAF V600E Status in Papillary Thyroid Cancer.

Shen X, Zhu G, Liu R, Viola D, Elisei R, Puxeddu E, Fugazzola L, Colombo C, Jarzab B, Czarniecka A, Lam AK, Mian C, Vianello F, Yip L, Riesco-Eizaguirre G, Santisteban P, O'Neill CJ, Sywak MS, Clifton-Bligh R, Bendlova B, Sýkorová V, Xing M.

J Clin Oncol. 2018 Feb 10;36(5):438-445. doi: 10.1200/JCO.2017.74.5497. Epub 2017 Dec 14.

19.

8th edition of the AJCC/TNM staging system of thyroid cancer: what to expect (ITCO#2).

Lamartina L, Grani G, Arvat E, Nervo A, Zatelli MC, Rossi R, Puxeddu E, Morelli S, Torlontano M, Massa M, Bellantone R, Pontecorvi A, Montesano T, Pagano L, Daniele L, Fugazzola L, Ceresini G, Bruno R, Rossetto R, Tumino S, Centanni M, Meringolo D, Castagna MG, Salvatore D, Nicolucci A, Lucisano G, Filetti S, Durante C.

Endocr Relat Cancer. 2018 Mar;25(3):L7-L11. doi: 10.1530/ERC-17-0453. Epub 2017 Nov 30. No abstract available.

20.

Long-term efficacy and safety of fourth-line multikinase inhibitor treatment with lenvatinib in a young papillary thyroid carcinoma patient.

Morelli S, Puxeddu E.

Drugs Context. 2017 Jul 26;6:212310. doi: 10.7573/dic.212310. eCollection 2017.

21.

BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment.

Huang Y, Qu S, Zhu G, Wang F, Liu R, Shen X, Viola D, Elisei R, Puxeddu E, Fugazzola L, Colombo C, Jarzab B, Czarniecka A, Lam AK, Mian C, Vianello F, Yip L, Riesco-Eizaguirre G, Santisteban P, O'Neill CJ, Sywak MS, Clifton-Bligh R, Bendlova B, Sýkorová V, Xing M.

J Natl Cancer Inst. 2018 Apr 1;110(4):362-370. doi: 10.1093/jnci/djx227.

22.

An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations?

Cazzola M, Rogliani P, Puxeddu E, Ora J, Matera MG.

Expert Rev Respir Med. 2018 Jan;12(1):43-54. doi: 10.1080/17476348.2018.1398086. Epub 2017 Nov 3. Review.

PMID:
29082808
23.

Are Evidence-Based Guidelines Reflected in Clinical Practice? An Analysis of Prospectively Collected Data of the Italian Thyroid Cancer Observatory.

Lamartina L, Durante C, Lucisano G, Grani G, Bellantone R, Lombardi CP, Pontecorvi A, Arvat E, Felicetti F, Zatelli MC, Rossi R, Puxeddu E, Morelli S, Torlontano M, Crocetti U, Montesano T, Giubbini R, Orlandi F, Aimaretti G, Monzani F, Attard M, Francese C, Antonelli A, Limone P, Rossetto R, Fugazzola L, Meringolo D, Bruno R, Tumino S, Ceresini G, Centanni M, Monti S, Salvatore D, Spiazzi G, Mian C, Persani L, Barbaro D, Nicolucci A, Filetti S.

Thyroid. 2017 Dec;27(12):1490-1497. doi: 10.1089/thy.2017.0299. Epub 2017 Nov 10.

PMID:
29020892
24.

Temporal Changes in Thyroid Nodule Volume: Lack of Effect on Paranodular Thyroid Tissue Volume.

Grani G, Bruno R, Lucisano G, Costante G, Meringolo D, Puxeddu E, Torlontano M, Tumino S, Attard M, Lamartina L, Nicolucci A, Cooper DS, Filetti S, Durante C.

Thyroid. 2017 Nov;27(11):1378-1384. doi: 10.1089/thy.2017.0201. Epub 2017 Sep 14.

PMID:
28806880
25.

Adherence to COPD treatment: Myth and reality.

Rogliani P, Ora J, Puxeddu E, Matera MG, Cazzola M.

Respir Med. 2017 Aug;129:117-123. doi: 10.1016/j.rmed.2017.06.007. Epub 2017 Jun 13. Review.

26.

Acromegaly is associated with increased cancer risk: a survey in Italy.

Terzolo M, Reimondo G, Berchialla P, Ferrante E, Malchiodi E, De Marinis L, Pivonello R, Grottoli S, Losa M, Cannavo S, Ferone D, Montini M, Bondanelli M, De Menis E, Martini C, Puxeddu E, Velardo A, Peri A, Faustini-Fustini M, Tita P, Pigliaru F, Peraga G, Borretta G, Scaroni C, Bazzoni N, Bianchi A, Berton A, Serban AL, Baldelli R, Fatti LM, Colao A, Arosio M; Italian Study Group of Acromegaly.

Endocr Relat Cancer. 2017 Sep;24(9):495-504. doi: 10.1530/ERC-16-0553. Epub 2017 Jul 14.

27.

The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer.

Wang F, Yu X, Shen X, Zhu G, Huang Y, Liu R, Viola D, Elisei R, Puxeddu E, Fugazzola L, Colombo C, Jarzab B, Czarniecka A, Lam AK, Mian C, Vianello F, Yip L, Riesco-Eizaguirre G, Santisteban P, O'Neill CJ, Sywak MS, Clifton-Bligh R, Bendlova B, Sýkorová V, Wang Y, Liu S, Zhao J, Zhao S, Xing M.

J Clin Endocrinol Metab. 2017 Sep 1;102(9):3241-3250. doi: 10.1210/jc.2017-00277.

28.

Gender-related Responsiveness to the Pharmacological Treatment of COPD: A First Step Towards the Personalized Medicine.

Calzetta L, Puxeddu E, Rogliani P.

EBioMedicine. 2017 May;19:14-15. doi: 10.1016/j.ebiom.2017.04.035. Epub 2017 Apr 28.

29.

Erratum to: Long-term safety and efficacy of Omnitrope® in adults with growth hormone deficiency: Italian interim analysis of the PATRO Adults study.

Ferone D, Profka E, Gasco V, Ambrosio MR, Colao A, Di Somma C, Puxeddu E, Arnaldi G, Pagano C, Zecchi E, Pietropoli A, Beck-Peccoz P.

J Endocrinol Invest. 2017 Jun;40(6):679-681. doi: 10.1007/s40618-017-0664-4. No abstract available.

PMID:
28421564
30.

Silencing of hTERT blocks growth and migration of anaplastic thyroid cancer cells.

Maggisano V, Celano M, Lombardo GE, Lepore SM, Sponziello M, Rosignolo F, Verrienti A, Baldan F, Puxeddu E, Durante C, Filetti S, Damante G, Russo D, Bulotta S.

Mol Cell Endocrinol. 2017 Jun 15;448:34-40. doi: 10.1016/j.mce.2017.03.007. Epub 2017 Mar 10.

PMID:
28288903
31.

Relationship between oxytocin/vasopressin and latex in obstetric surgery: how to recognize (and prevent) allergic reactions and differentiate them from side effects?

Liccardi G, Calzetta L, Salzillo A, Puxeddu E, Rogliani P.

J Allergy Clin Immunol Pract. 2017 May - Jun;5(3):873. doi: 10.1016/j.jaip.2016.10.023. Epub 2017 Mar 9. No abstract available.

PMID:
28286159
32.

Optimizing drug delivery in COPD: The role of inhaler devices.

Rogliani P, Calzetta L, Coppola A, Cavalli F, Ora J, Puxeddu E, Matera MG, Cazzola M.

Respir Med. 2017 Mar;124:6-14. doi: 10.1016/j.rmed.2017.01.006. Epub 2017 Jan 24. Review.

33.

Impact of pulmonary vascular volume on mortality in IPF: is it time to reconsider the role of vasculature in disease pathogenesis and progression?

Puxeddu E, Cavalli F, Pezzuto G, Teodori E, Rogliani P.

Eur Respir J. 2017 Feb 23;49(2). pii: 1602345. doi: 10.1183/13993003.02345-2016. Print 2017 Feb. No abstract available.

34.

Long-term safety and efficacy of Omnitrope® in adults with growth hormone deficiency: Italian interim analysis of the PATRO Adults study.

Ferone D, Profka E, Gasco V, Ambrosio MR, Colao A, Di Somma C, Puxeddu E, Arnaldi G, Pagano C, Zecchi E, Pietropoli A, Beck-Peccoz P.

J Endocrinol Invest. 2017 Jun;40(6):669-678. doi: 10.1007/s40618-016-0604-8. Epub 2017 Feb 4. Erratum in: J Endocrinol Invest. 2017 Jun;40(6):679-681.

35.

LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment.

Calzetta L, Rogliani P, Ora J, Puxeddu E, Cazzola M, Matera MG.

Eur Respir Rev. 2017 Jan 17;26(143). pii: 160043. doi: 10.1183/16000617.0043-2016. Print 2017 Jan. Review.

36.

Is Allergic Sensitization to Siberian Hamster Preventable in High-Risk Individuals Who Are Already Sensitized or Exposed to Furry Animals?

Liccardi G, Salzillo A, Calzetta L, Piccolo A, Puxeddu E, Rogliani P.

J Investig Allergol Clin Immunol. 2016;26(6):403-405. doi: 10.18176/jiaci.0100. No abstract available.

37.

Signal Transducer and Activator of Transcription 1 Plays a Pivotal Role in RET/PTC3 Oncogene-induced Expression of Indoleamine 2,3-Dioxygenase 1.

Moretti S, Menicali E, Nucci N, Voce P, Colella R, Melillo RM, Liotti F, Morelli S, Fallarino F, Macchiarulo A, Santoro M, Avenia N, Puxeddu E.

J Biol Chem. 2017 Feb 3;292(5):1785-1797. doi: 10.1074/jbc.M116.745448. Epub 2016 Dec 19.

38.

Airflow obstruction: is it asthma or is it COPD?

Rogliani P, Ora J, Puxeddu E, Cazzola M.

Int J Chron Obstruct Pulmon Dis. 2016 Nov 30;11:3007-3013. eCollection 2016. Review.

39.

The Time Course of Pulmonary Function Tests in COPD Patients with Different Levels of Blood Eosinophils.

Rogliani P, Puxeddu E, Ciaprini C, Ora J, Onorato A, Pezzuto G, Calzetta L, Cazzola M.

Biomed Res Int. 2016;2016:4547953. Epub 2016 Oct 16.

40.

Acute liver damage following intravenous glucocorticoid treatment for Graves' ophthalmopathy.

Moleti M, Giuffrida G, Sturniolo G, Squadrito G, Campennì A, Morelli S, Puxeddu E, Sisti E, Trimarchi F, Vermiglio F, Marinò M.

Endocrine. 2016 Oct;54(1):259-268. Epub 2016 Mar 22. Review.

PMID:
27003434
41.

Dual bronchodilation and exacerbations of COPD.

Cazzola M, Ora J, Puxeddu E.

J Thorac Dis. 2016 Sep;8(9):2383-2386. No abstract available.

42.

Onset of action of budesonide/formoterol Spiromax(®) compared with budesonide/formoterol Turbuhaler(®) in patients with COPD.

Cazzola M, Ora J, Di Paolo A, Puxeddu E, Calzetta L, Rogliani P.

Pulm Pharmacol Ther. 2016 Aug;39:48-53. doi: 10.1016/j.pupt.2016.06.006. Epub 2016 Jun 22.

PMID:
27344046
43.

Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells.

Cazzola M, Calzetta L, Puxeddu E, Ora J, Facciolo F, Rogliani P, Matera MG.

Respir Res. 2016 Jun 13;17(1):70. doi: 10.1186/s12931-016-0386-8.

44.

An unusual outbreak of nontuberculous mycobacteria in hospital respiratory wards: Association with nontuberculous mycobacterial colonization of hospital water supply network.

D'Antonio S, Rogliani P, Paone G, Altieri A, Alma MG, Cazzola M, Puxeddu E.

Int J Mycobacteriol. 2016 Jun;5(2):244-7. doi: 10.1016/j.ijmyco.2016.04.001. Epub 2016 May 6.

45.

Olodaterol + tiotropium bromide for the treatment of COPD.

Calzetta L, Ciaprini C, Puxeddu E, Cazzola M.

Expert Rev Respir Med. 2016 Apr;10(4):379-386. doi: 10.1586/17476348.2016.1156538. Epub 2016 Mar 22.

PMID:
26894830
46.

Interaction between corticosteroids and muscarinic antagonists in human airways.

Cazzola M, Calzetta L, Rogliani P, Puxeddu E, Facciolo F, Matera MG.

Pulm Pharmacol Ther. 2016 Feb;36:1-9. doi: 10.1016/j.pupt.2015.11.004. Epub 2015 Nov 30.

PMID:
26656790
47.

Timing of breakfast does not influence therapeutic efficacy of liquid levothyroxine formulation.

Morelli S, Reboldi G, Moretti S, Menicali E, Avenia N, Puxeddu E.

Endocrine. 2016 Jun;52(3):571-8. doi: 10.1007/s12020-015-0788-2. Epub 2015 Nov 4.

PMID:
26537478
48.

Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants.

Shi X, Liu R, Basolo F, Giannini R, Shen X, Teng D, Guan H, Shan Z, Teng W, Musholt TJ, Al-Kuraya K, Fugazzola L, Colombo C, Kebebew E, Jarzab B, Czarniecka A, Bendlova B, Sykorova V, Sobrinho-Simões M, Soares P, Shong YK, Kim TY, Cheng S, Asa SL, Viola D, Elisei R, Yip L, Mian C, Vianello F, Wang Y, Zhao S, Oler G, Cerutti JM, Puxeddu E, Qu S, Wei Q, Xu H, O'Neill CJ, Sywak MS, Clifton-Bligh R, Lam AK, Riesco-Eizaguirre G, Santisteban P, Yu H, Tallini G, Holt EH, Vasko V, Xing M.

J Clin Endocrinol Metab. 2016 Jan;101(1):264-74. doi: 10.1210/jc.2015-2917. Epub 2015 Nov 3.

49.

Searching for the synergistic effect between aclidinium and formoterol: From bench to bedside.

Cazzola M, Calzetta L, Ora J, Puxeddu E, Rogliani P, Matera MG.

Respir Med. 2015 Oct;109(10):1305-11. doi: 10.1016/j.rmed.2015.08.005. Epub 2015 Aug 13.

50.

Structured multidisciplinary discussion of HRCT scans for IPF/UIP diagnosis may result in indefinite outcomes.

Pezzuto G, Claroni G, Puxeddu E, Fusco A, Cavalli F, Altobelli S, Portalone S, Zompatori M, Simonetti G, Saltini C, Sergiacomi G.

Sarcoidosis Vasc Diffuse Lung Dis. 2015 Jun 22;32(1):32-6.

PMID:
26237353

Supplemental Content

Loading ...
Support Center